Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy.
Infectious Disease Unit, University Hospital of Pisa, Pisa, Italy.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02562-17. Print 2018 Jun.
A significant cause of mortality in the intensive care unit (ICU) is multidrug-resistant (MDR) Gram-negative bacteria, such as MDR (MDR-AB) and carbapenemase-producing (KPC-Kp). The aim of the present study was to compare the clinical features, therapy, and outcome of patients who developed septic shock due to either MDR-AB or KPC-Kp. We retrospectively analyzed patients admitted to the ICU of a teaching hospital from November 2010 to December 2015 who developed septic shock due to MDR-AB or KPC-Kp infection. Data from 220 patients were analyzed: 128 patients (58.2%) were diagnosed with septic shock due to KPC-Kp, and 92 patients (41.8%) were diagnosed with septic shock due to MDR-AB. The 30-day mortality rate was significantly higher for the MDR-AB group than the KPC-Kp group (84.8% versus 44.5%, respectively; < 0.001). Steroid exposure and pneumonia were associated with MDR-AB infection, whereas hospitalization in the previous 90 days, primary bacteremia, and KPC-Kp colonization were associated with KPC-Kp infection. For patients with KPC-Kp infections, the use of ≥2 -active antibiotics as empirical or definitive therapy was associated with higher 30-day survival, while isolation of colistin-resistant strains was linked to mortality. Patients with MDR-AB infections, age >60 years, and a simplified acute physiology score II (SAPS II) of >45 points were associated with increased mortality rates. We concluded that septic shock due to MDR-AB infection is associated with very high mortality rates compared to those with septic shock due to KPC-Kp. Analysis of the clinical features of these critically ill patients might help physicians in choosing appropriate empirical antimicrobial therapy.
在重症监护病房(ICU)中,多重耐药(MDR)革兰氏阴性菌(如 MDR-AB 和产碳青霉烯酶(KPC)的肺炎克雷伯菌)是导致死亡率的重要原因。本研究旨在比较因 MDR-AB 或 KPC-Kp 引起的败血症性休克患者的临床特征、治疗和结局。我们回顾性分析了 2010 年 11 月至 2015 年 12 月入住我院 ICU 的因 MDR-AB 或 KPC-Kp 感染导致败血症性休克的患者。共分析了 220 例患者的数据:128 例(58.2%)患者因 KPC-Kp 引起败血症性休克,92 例(41.8%)患者因 MDR-AB 引起败血症性休克。MDR-AB 组的 30 天死亡率明显高于 KPC-Kp 组(84.8%比 44.5%;<0.001)。皮质类固醇暴露和肺炎与 MDR-AB 感染有关,而住院前 90 天、原发性菌血症和 KPC-Kp 定植与 KPC-Kp 感染有关。对于 KPC-Kp 感染患者,使用≥2 种活性抗生素进行经验性或确定性治疗与较高的 30 天生存率相关,而分离到粘菌素耐药株与死亡率相关。MDR-AB 感染患者、年龄>60 岁和简化急性生理学评分 II(SAPS II)>45 分与死亡率增加相关。我们得出结论,与因 KPC-Kp 引起的败血症性休克相比,因 MDR-AB 感染引起的败血症性休克的死亡率非常高。分析这些重症患者的临床特征可能有助于医生选择合适的经验性抗菌治疗。